Effects of adenosine and defibrotide adjunct to a standard crystalloid cardioplegic solution

Journal of Cardiovascular Surgery

Volumn 46, Issue 3, 2005, Pages 291-296

  Mantovani, Vit ^a   Mariscalco, G ^a   Borsani, P ^a   Tenconi, S ^a   Bruno, V D ^a   Leva, C ^a   Ferrarese, S ^a   Sala, A ^a  

^a UNIVERSITY OF INSUBRIA   (Italy)

Author keywords

Adenosine; Cardioplegia; Defibrotide

Indexed keywords

ADENOSINE; BICARBONATE; BUFFER; CALCIUM CHLORIDE; CARDIOPLEGIC AGENT; CREATINE KINASE; DEFIBROTIDE; GLUCOSE; LACTATE DEHYDROGENASE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM DIHYDROGEN PHOSPHATE; ST THOMAS HOSPITAL SOLUTION;

ANIMAL TISSUE; ARTICLE; CARDIOPLEGIA; CONTROLLED STUDY; DRUG MECHANISM; HEART ARREST; HEART PERFUSION; HEART RATE; ISOLATED HEART; MALE; NONHUMAN; RAT; REPERFUSION; STATISTICAL SIGNIFICANCE; TEMPERATURE;

ADENOSINE; ANIMALS; CARDIOPLEGIC SOLUTIONS; CORONARY CIRCULATION; DISEASE MODELS, ANIMAL; DRUG COMBINATIONS; FIBRINOLYTIC AGENTS; HEART ARREST, INDUCED; HEART RATE; MALE; MYOCARDIAL ISCHEMIA; POLYDEOXYRIBONUCLEOTIDES; RATS; RATS, WISTAR; RECOVERY OF FUNCTION; VASODILATOR AGENTS;

EID: 30544441038     PISSN: 00219509     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Wilbur SL, Marchlinski FE. Adenosine as an antiarrhythmic agent. Am J Cardiol 1997;79:30-7.
2. Lasley RD, Konyn PJ, Hegge JO, Mentzer RM Jr. Effects of ischemic and adenosine preconditioning on interstitial fluid adenosine and myocardial infarct size. Am J Physiol 1995;269:H1460-6.
3. Berti F, Rossoni G, Niada R, Omini C, Pretolani M, Mandelli C. Beneficial effects of defibrotide against myocardial ischemia and decline of beta-adrenoceptor function in the rabbit. Haemostasis 1986;16 Suppl 1:13-7.
4. Niada R, Porta R, Pescador R, Mantovani M, Prino G. Cardioprotective effects of defibrotide in acute myocardial ischemia in the cat. Thromb Res 1985;38:71-81.
5. Bianchi G, Barone D, Lanzarotti E, Tettamanti R, Porta R, Moltrasio D et al. Defibrotide, a single-stranded polydeoxyribonucleotide acting as an adenosine receptor agonist. Eur J Pharmacol 1993;238: 327-34.
6. Alberico P, Porta R, Pescador R, Ferro L. Is defibrotide's activity on leukocytes adenosine-receptor mediated? An "in vitro" - "ex vivo" appraisal. Thromb Res 1995;80:281-9.
7. Leesar MA, Stoddard M, Ahmed M, Broadbent J, Bolli R. Preconditioning of human myocardium with adenosine during coronary angioplasty. Circulation 1997;95:2500-7.
8. Lasley RD, Mentzer RM Jr. Adenosine improves recovery of postischemic myocardial function via an adenosine A1 receptor mechanism. Am J Physiol 1992;263:H1460-5.
9. Lasley RD, Mentzer RM Jr. Protective effects of adenosine in the reversibly injured heart. Ann Thorac Surg 1995;60:843-6.
10. Kilpatrick EL, Narayan P, Mentzer RM Jr, Lasley RD. Cardiac myocyte adenosine A2a receptor activation fails to alter cAMP or contractility: role of receptor localization. Am J Physiol Heart Circ Physiol 2002;282:H1035-40.
11. Lasley RD, Jahania MS, Mentzer RM Jr. Beneficial effects of adenosine A(2a) agonist CGS-21680 in infarcted and stunned porcine myocardium. Am J Physiol Heart Circ Physiol 2001;280:H1660-6.
12. Lasley RD, Smart EJ. Cardiac myocyte adenosine receptors and caveolae. Trends Cardiovasc Med 2001;11:259-63.
13. Auchampach JA, Rizvi A, Qiu Y, Tang XL, Maldonado C, Teschner S et al. Selective activation of A3 adenosine receptors with N6-(3-iodobenzyl) adenosine-5′-N-methyluronamide protects against myocardial stunning and infarction without hemodynamic changes in conscious rabbits. Circ Res 1997;80:800-9.
14. Lasley RD, Zhou Z, Hegge JO, Bunger R, Mentzer RM Jr. Adenosine attenuates in vivo myocardial stunning with minimal effects on cardiac energetics. Basic Res Cardiol 1998;93:303-12.
15. Jordan JE, Zhao ZQ, Sato H, Taft S, Vinten-Johansen J. Adenosine A2 receptor activation attenuates reperfusion injury by inhibiting neutrophil accumulation, superoxide generation and coronary endothelial adherence. J Pharmacol Exp Ther 1997;280:301-9.
16. Zhao ZQ, Todd JC, Sato H, Ma XL, Vinten-Johansen J. Adenosine inhibition of neutrophil damage during reperfusion does not involve K(ATP)-channel activation. Am J Physiol 1997;273:H1677-87.
17. Hudspeth DA, Nakanishi K, Vinten-Johansen J, Zhao ZQ, McGee DS, Williams MW et al. Adenosine in blood cardioplegia prevents postischemic dysfunction in ischemically injured hearts. Ann Thorac Surg 1994;58:1637-44.
18. Mentzer RM Jr, Birjiniuk V, Khuri S, Lowe JE, Rahko PS, Weisel RD et al. Adenosine myocardial protection: preliminary results of a phase II clinical trial. Ann Surg 1999;229:643-9; discussion 649-50.
19. Pescador R, Porta R, Ferro L. An integrated view of the activities of defibrotide. Semin Thromb Hemost 1996;22 Suppl 1:71-5.
20. Palmer KJ, Goa KL. Defibrotide. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in vascular disorders. Drugs 1993;45:259-94.
21. Porta R, Pescador R, Mantovani M, Prino G. Defibrotide affects the anticoagulant and lipase-releasing activities of heparin. Haemostasis 1990;20:347-56.
22. Rossoni G, Berti F, Trento F, Cattaneo F, Porta R, Pescador R et al. Chronic oral defibrotide counteracts hypercholesterolemia noxious effects on cardiovascular function in the rabbit. Thromb Res 1999;94:327-38.
23. Porta R, Conz A, Conto A, Pescador R, Mantovani M, Ferro L. Comparable beneficial effects of defibrotide and nifedipine in calcium induced atherosclerosis. Life Sci 1994;54:799-812.
24. Hohlfeld T, Bucha E, Nowak G, Bruggener E, Strobach H, Schror K. Favourable effect of defibrotide in lipid A-induced shock in pigs. Circ Shock 1992;38:122-9.
25. Tettamanti R, Bianchi G, Vitte PA, Kato G, Porta R, Thiemermann C et al. A novel insight into the mechanism of the antithrombotic action of defibrotide. Life Sci 1992;51:1545-55.
26. Haklar G, Ersahin C, Moini H, Sungun M, Dogan N, Bilsel S et al. Involvement of free radicals in the cardioprotective effect of defibrotide. Arzneimittelforschung 1996;46:381-4.
27. Rossoni G, Pompilio G, Biglioli P, Alamanni F, Tartara P, Rona P et al. Protectant activity of defibrotide in cardioplegia followed by ischemia/ reperfusion injury in the isolated rat heart. J Card Surg 1999;14:334-41.
28. Niada R, Porta R, Pescador R, Mantovani M, Prino G, Berti F. Cardioprotective effects of defibrotide in acute lethal and nonlethal myocardial ischemia in the cat. Haemostasis 1986;16 Suppl 1:18-25.
29. Ferrero ME, Corsi M, Marni A, Gaja G. Efficacy of defibrotide treatment in favoring the function of the grafted heart and kidney in rats. Transplant Proc 1994;26:251-2.
30. Ma XL, Porta R, Pescador R, Lefer AM. Novel beneficial mechanisms of defibrotide, a prostacyclin enhancing agent in splanchnic artery occlusion and reperfusion in rats. Methods Find Exp Clin Pharmacol 1991;13:667-74.
31. Thiemermann C, Ney P, Schror K. Protection of the ischaemic myocardium from reperfusion injury by defibrotide and its possible mechanism of action. Biomed Biochim Acta 1988;47:S19-22.
32. Berti F, Rossoni G, Niada R, Folco G, Omini C, Tondo C. Defibrotide, an antithrombotic substance that preserves postsynaptic alpha- and beta-adrenergic function in post acute infarcted rabbit hearts. J Cardiovasc Pharmacol 1986;8:235-40.